ALG-170675
- Indication
- healthy volunteers, followed by multiple doses in participants with chronic HBV
- Stage
- phase0
- Event
- Conference Presentation
- Details
October 5, 2026: Aligos Therapeutics (NASDAQ: ALGS) said five abstracts were accepted for presentation at AASLD The Liver Meeting 2026 in Denver (November 5-9, 2026).
Pevifoscorvir sodium (CAM-E), chronic HBV: three abstracts will be presented on November 8, 2026. Topics include immune-modulatory effects in HBeAg-positive chronic HBV patients; long-term on-study treatment reducing HBsAg levels to below 3000 IU/mL in HBeAg-positive subjects; and in vitro data showing pevifoscorvir sodium was superior to nucleos(t)ide analogs in suppressing HBV double-stranded linear DNA. One poster was designated a Poster of Distinction.
ALG-170675, chronic HBV: a November 8, 2026 abstract will present preclinical data describing efficacy in an AAV-HBV mouse model plus pharmacokinetics and safety in mouse and monkey.
ALG-215007, hepatitis delta virus: a November 7, 2026 preclinical abstract will present potent inhibition of HDV replication by this antisense oligonucleotide.
The catalyst is conference data presentation at AASLD, with abstracts already released on the meeting website.
- Source
- View catalyst source ↗